{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-015319","form_type":"8-K","ticker":"SNGX","cik":"0000812796","company_name":"SOLIGENIX, INC.","filed_at":"2022-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.636132+00:00","generated_at":"2026-06-23T01:30:13.073988+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Soligenix forms Psoriasis Medical Advisory Board; Phase 2a study starts December 2022","bullets":["Formed Medical Advisory Board (MAB) for SGX302 (synthetic hypericin) in mild-to-moderate psoriasis.","Phase 2a clinical study anticipated to begin in December 2022; FDA previously cleared IND and protocol.","MAB chaired by Neal Bhatia, MD (Therapeutics Clinical Research, San Diego).","Previous positive Phase 3 trial of HyBryte (same synthetic hypericin) in CTCL supports psoriasis program.","Psoriasis affects >7.5 million patients in the U.S.; MAB includes four board-certified dermatologists."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-015319","json":"https://secwatch.observer/filing/0001558370-22-015319.json","markdown":"https://secwatch.observer/filing/0001558370-22-015319.md","text":"https://secwatch.observer/filing/0001558370-22-015319.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/812796/000155837022015319/0001558370-22-015319-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/812796/000155837022015319/tmb-20221025x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:30:13.073988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}